NCT00523380View on ClinicalTrials.gov

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 4, 2007

Primary Completion Date

January 7, 2009

Study Completion Date

January 7, 2009

Conditions
CancerOvarian Cancer
Interventions
DRUG

recombinant interleukin-21

Administered i.v. in treatment cycles of 28 days.

DRUG

caelyx (pegylated liposomal doxorubicin)

Administered i.v. in treatment cycles of 28 days.

Trial Locations (7)

13273

Novo Nordisk Investigational Site, Marseille

35043

Novo Nordisk Investigational Site, Marburg

44805

Novo Nordisk Investigational Site, Saint-Herblain

45122

Novo Nordisk Investigational Site, Essen

65199

Novo Nordisk Investigational Site, Wiesbaden

69373

Novo Nordisk Investigational Site, Lyon

94805

Novo Nordisk Investigational Site, Villejuif

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY